Shares of health-care companies were flat as traders hedged their bets on the outlook for the sector's growth.
The second half of 2017 was marked by a wave of mergers that crossed traditional lines as drug store CVS Health agreed to buy insurer Aetna, among other silo-breaking deals.
Such deals are a result of adjustments to a reshaped health-care system in the U.S. and a likely slowdown in drug-price increases. Further, the price of health insurance looks set to rise in Affordable Care Act exchanges as a key tenet of that law, the penalty for not carrying insurance, was repealed under the Republican tax-cut bill.
The path forward for Apotex is uncertain following the sudden death of founder and Chairman Barry Sherman, who was the architect of the generic drugmaker's litigation-heavy strategy. Apotex was known for challenging drug companies' patents in court, allowing it to become the first to market with generic versions when such litigation succeeded.
A federal jury found Evan Greebel, a former corporate lawyer, guilty of charges that he helped former drug executive Martin Shkreli defraud Retrophin, a publicly traded pharmaceutical company that Mr. Shkreli helped found.
-Rob Curran, email@example.com
(END) Dow Jones Newswires
December 28, 2017 17:21 ET (22:21 GMT)